Table 2. Characteristics of the stereotactic treatments administered.

Patient	Days form systemic therapy to surgery	TKI withdrawal days before surgery	Anti-PD-1 antibody withdrawal before surgery	Systemic therapy line	TKI used	Anti-PD-1 antibody used	TACE used (cycle, regimens)	Radiotherapy used (intension, cycle, site)
1	81	7	25	1	Len	Cam	Yes (1, 5-FU and L-OHP)	No
2	83	8	24	1	Len	NA	Yes (1, 5-FU and L-OHP)	No
3	804	8	37	1	Apa	Cam	Yes (3, 5-FU and L-OHP)	Yes (30 Gy, 15, hilar LN)
4	91	9	25	1	Len	Tor	Yes (1, 5-FU and L-OHP)	No
5	185	7	21	1	Len	Tis	No	Yes (30 Gy, 30, metastasis)
6	81	7	27	1	Len	Sin	No	No
7	323	7	30	1	Len	Cam	No	Yes (30 Gy, 20, metastasis)
8	95	7	33	1	Len	Tor	No	No
9	130	8	19	1	Len	Tor	Yes (2, 5-FU and L-OHP)	No

TKIs, tyrosine kinase inhibitors; PD-1, programmed death 1; Len, lenvatinib; Apa, apatinib; Sin, sintilimab; Cam, camrelizumab; Tis, tislelizumab; Tor, toripalimab; 5-FU, 5-fluorouracil; L-OHP, oxaliplatin; TACE, transarterial chemotherapy and embolization